Literature DB >> 7672492

Peripheral and hepatic insulin sensitivity in subjects with impaired glucose tolerance.

T S Berrish1, C S Hetherington, K G Alberti, M Walker.   

Abstract

Recent evidence suggests that the postprandial hyperglycaemia in impaired glucose tolerance is primarily due to impaired suppression of basal hepatic glucose output. This in turn appears to be secondary to decreased first phase insulin secretion, although decreased hepatic insulin sensitivity, which is a feature of non-insulin-dependent diabetes mellitus, might also play a role. Eight mildly overweight subjects with impaired glucose tolerance and eight closely matched control subjects with normal glucose tolerance underwent an intravenous glucose tolerance test to assess first phase insulin secretion. Insulin sensitivity was examined by a 150-min hyperinsulinaemic-euglycaemic clamp. Somatostatin was infused from 150 min to suppress endogenous insulin secretion, and glucagon and insulin were replaced by constant infusion. Glucose with added dideuterated glucose (labelled infusion technique) was infused to maintain euglycaemia. First phase insulin secretion (delta 0-10 min insulin area divided by delta 0-10 min glucose area) was significantly decreased in the subjects with impaired glucose tolerance (median [range]: 1.2 [0.2-19.4] vs 9.1 [2.6-14.5] mU.mmol-1; p < 0.01). During the clamp, circulating insulin (93 +/- 8 [mean +/- SEM] and 81 +/- 10 mU.l-1) and glucagon (54 +/- 4 and 44 +/- 6 ng.l-1) levels were comparable. Total glucose disposal was decreased in subjects with impaired glucose tolerance (2.78 +/- 0.27 vs 4.47 +/- 0.53 mg.kg-1.min-1; p < 0.02), and was primarily due to decreased non-oxidative glucose disposal. However, hepatic glucose output rates were comparable during the clamp (0.38 +/- 0.10 and 0.30 +/- 0.18 mg.kg-1.min-1).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7672492     DOI: 10.1007/bf00401842

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  27 in total

1.  Kinetics of glucose disposal in whole body and across the forearm in man.

Authors:  H Yki-Järvinen; A A Young; C Lamkin; J E Foley
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

2.  Hepatic glucose output in humans measured with labeled glucose to reduce negative errors.

Authors:  J C Levy; G Brown; D R Matthews; R C Turner
Journal:  Am J Physiol       Date:  1989-10

3.  Insulin action in non-insulin-dependent diabetes mellitus: the relationship between hepatic and extrahepatic insulin resistance and obesity.

Authors:  R Firth; P Bell; R Rizza
Journal:  Metabolism       Date:  1987-11       Impact factor: 8.694

4.  Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus.

Authors:  J Eriksson; A Franssila-Kallunki; A Ekstrand; C Saloranta; E Widén; C Schalin; L Groop
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

5.  Evidence for impaired pancreatic beta cell function in South African Indians with impaired glucose tolerance.

Authors:  A A Motala; M A Omar
Journal:  Diabet Med       Date:  1994-06       Impact factor: 4.359

6.  Enzyme immunoassay for intact human insulin in serum or plasma.

Authors:  L Andersen; B Dinesen; P N Jørgensen; F Poulsen; M E Røder
Journal:  Clin Chem       Date:  1993-04       Impact factor: 8.327

7.  In-vivo measurement of glucose and alanine metabolism with stable isotopic tracers.

Authors:  D M Bier; K J Arnold; W R Sherman; W H Holland; W F Holmes; D M Kipnis
Journal:  Diabetes       Date:  1977-11       Impact factor: 9.461

8.  Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians.

Authors:  S Lillioja; D M Mott; B V Howard; P H Bennett; H Yki-Järvinen; D Freymond; B L Nyomba; F Zurlo; B Swinburn; C Bogardus
Journal:  N Engl J Med       Date:  1988-05-12       Impact factor: 91.245

9.  Incomplete suppression of hepatic glucose production in non-insulin dependent diabetes mellitus measured with [6,6-2H2]glucose enriched glucose infusion during hyperinsulinaemic euglycaemic clamps.

Authors:  J K Powrie; G D Smith; T R Hennessy; F Shojaee-Moradie; J M Kelly; P H Sönksen; R H Jones
Journal:  Eur J Clin Invest       Date:  1992-04       Impact factor: 4.686

10.  Impaired glucose tolerance in obesity is associated with insensitivity to insulin in multiple aspects of metabolism as assessed by a low dose incremental insulin infusion technique.

Authors:  D A Robertson; B M Singh; M Nattrass
Journal:  Diabet Med       Date:  1991-10       Impact factor: 4.359

View more
  4 in total

1.  Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.

Authors:  Zhimin Huang; Xuesi Wan; Juan Liu; Wanping Deng; Ailing Chen; Liehua Liu; Jianbin Liu; Guohong Wei; Hai Li; Donghong Fang; Yanbing Li
Journal:  Diabetes Technol Ther       Date:  2013-08-30       Impact factor: 6.118

2.  Comparative evaluation of whole body and hepatic insulin resistance using indices from oral glucose tolerance test in morbidly obese subjects with nonalcoholic Fatty liver disease.

Authors:  Kamran Qureshi; Ronald H Clements; Fahad Saeed; Gary A Abrams
Journal:  J Obes       Date:  2010-06-08

3.  Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance.

Authors:  E Ferrannini; A Gastaldelli; Y Miyazaki; M Matsuda; M Pettiti; A Natali; A Mari; R A DeFronzo
Journal:  Diabetologia       Date:  2003-07-23       Impact factor: 10.122

Review 4.  Ectopic Fat Accumulation in Distinct Insulin Resistant Phenotypes; Targets for Personalized Nutritional Interventions.

Authors:  Inez Trouwborst; Suzanne M Bowser; Gijs H Goossens; Ellen E Blaak
Journal:  Front Nutr       Date:  2018-09-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.